Bioheart Pursues OrCel Cardiac Regeneration; Ortec Chases Ulcer Claims

Bioheart, Inc.'s Myocell may provide Ortec entry into the cardiovascular regeneration market, under a deal covering the cell transplantation product in combination with Ortec's OrCel collagen sponge and vascular endothelial growth factor technologies